Alex Knaster is Chairman and CEO of Pamplona Capital Management, an investment management firm he founded in 2004, with private equity, hedge fund and fund of funds operations. Alex has more than 25 years of experience in the investment banking
Michele Cleary joined The Mark Foundation as CEO in January 2017. Prior to that, she was Vice President of Clinical Translation Technologies & Operations at Bristol-Myers Squibb where she led biomarker research for cancer and other diseases.
Steven H. Bernstein, MD joined The Mark Foundation as its Chief Medical Officer in February 2018. He also serves as the Senior Vice President for Clinical Research and Development at Turnstone Biologics. Previously, Dr. Bernstein served as Chair, Immuno-Oncology Translational
Rebecca joined The Mark Foundation as Scientific Program Director in November 2017. She came to The Mark Foundation from D. E. Shaw Research, a firm engaged in scientific research and technological development in the field of computational biochemistry.
Maiya Guidry joined The Mark Foundation as Administrative Assistant in January 2018. Maiya comes to us with years of Administrative and Office support experience. Prior to joining the team, Maiya worked in the fashion industry as a Production Assistant at
Christa Justus joined The Mark Foundation as Chief Grants Management & Communications Officer in July 2017. She came to the Foundation directly from Gabrielle’s Angel Foundation for Cancer Research where she served as Director of Grants and Chief Content Officer.
Patrick Lewis joined The Mark Foundation as Head of Operations and Finance in May 2017. Prior to joining The Mark Foundation, Patrick was at Merck and Co., in diverse roles with increasing responsibility.
Ryan Schoenfeld joined The Mark Foundation as Senior Scientific Program Director in January 2018. Previously, he was Senior Director of Data Sciences at Janssen Pharmaceutical Companies of Johnson & Johnson, where he led a team of computational scientists delivering high
Dr. Levine is a physician-scientist and Member of the Human Oncology and Pathogenics Program; and Attending Physician on the Leukemia Service, Department of Medicine; the Laurence Joseph Dineen Chair in Leukemia Research; and the director of the Memorial Sloan Kettering
Dr. Scott A. Armstrong is Chairman of the Department of pediatric Oncology at Dana-Farber Cancer Institute, and the David G. Nathan Professor of Pediatrics at Harvard Medical School. Dr. Armstrong received his MD and PhD from the University of Texas
Dr. Civin is a pioneer in cancer and stem cell research who is known internationally for developing a way to isolate stem cells from other blood cells. He has received wide recognition for his groundbreaking discovery of the CD34 antibody,
Dr. Elaine Mardis graduated from the University of Oklahoma with a BS in zoology and completed her PhD in Chemistry and Biochemistry in 1989, also at Oklahoma. Dr. Mardis was a senior research scientist for four years at BioRad Laboratories.
Dr. Jeroen Roose is a tenured Principal Investigator and Vice Chair of Anatomy at the University of California, San Francisco. He is also a co-founder of UCSF’s ImmunoX. During his PhD, he trained with Professor Hans Clevers and investigated Wnt
Dr. Velculescu is internationally known for his discoveries in genomics and cancer research. He and his colleagues performed the first sequence analysis of the coding genome in human cancers, identifying key genes and pathways dysregulated in tumorigenesis. He developed SAGE
Dr. E. John Wherry is the Director of the Institute for Immunology and Professor of Microbiology at the University of Pennsylvania. Dr. Wherry's expertise focuses on T cell exhaustion in chronic infections and cancer.